Quantcast
Last updated on April 19, 2014 at 21:20 EDT

The Chronic Pain Drug Market Will Attain $21.6 Billion in Major-Market Sales by 2022

December 12, 2013

Generic Erosion Will Dominate in the Near Term, According to Findings from Decision Resources

BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will decrease from $21.4 billion in 2012 to $18.3 billion in 2017, but will recover to $21.6 billion by 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

“The sales pattern in the total chronic pain market is attributable to the loss of market exclusivity for key chronic pain therapies, including controlled-release oxycodone (Purdue Pharma/Mundipharma/Napp Pharmaceuticals’ OxyContin), over the next five years,” said Decision Resources Principal Business Insights Analyst Natalie Taylor, Ph.D. “Market contraction in the first half of the forecast period will be followed by a growth in sales from 2017 through 2022, driven by the launches of a number of emerging therapies.”

The Pharmacor report entitled Chronic Pain also finds that the pipeline of therapies in clinical development for chronic pain conditions continues to be composed largely of reformulations of existing molecules–however, agents with novel mechanisms of action, such as subtype-selective sodium channel blockers and monoclonal antibodies against nerve growth factor (NGF), have made recent and notable developmental advances. Overcoming delays due to safety concerns, anti-NGF therapies such as Eli Lilly/Pfizer’s tanezumab and Johnson & Johnson/Takeda’s fulranumab are forecast to garner significant sales from use in patients with severe, treatment-refractory osteoarthritis pain or chronic low back pain. This class will comprise 19 percent of major-market sales for chronic pain therapies by 2022.

The report also highlights that effective analgesics with lower risk of tolerance and abuse remains a key area of unmet need in this market. Now that the FDA has established a regulatory path for abuse-deterrent, long-acting and extended-release opioids, several abuse-deterrent products from developers including Pfizer, Teva and Purdue are expected to launch in the United States over the next five years. In 2022, sales of abuse-deterrent opioid formulations attributed to chronic pain treatment will exceed $1 billion across the multiple chronic pain indications covered in the report.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources


Source: PR Newswire